Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Other blood cancers and transplant
Phase 1 INCA035784 bispecific mAb targeting CALRmut and CD3 in MPN
This Phase 1 open-label study of INCA035784—a bispecific antibody targeting CALR-mutant and CD3—is evaluating safety, tolerability, and optimal dosing in patients with myeloproliferative neoplasms, including…
NCT07008118 First-in-human - Trial result
Non-small cell lung cancer
Platinum Doublet Lifts 2-Year DFS to 96% in Gene-High Stage I–IIA NSCLC
Platinum-based adjuvant chemotherapy—mainly cisplatin or carboplatin doublets—was tested in the Phase 3 AIM-HIGH trial (NCT01817192), which randomized 200 resected stage IA-IIA non-squamous NSCLC patients flagged as…
NCT01817192 - Trial result Spotlight
Ovarian cancer
Avutometinib + Defactinib (RAF-MEK clamp / FAK blocker) Posts 42% ORR and 20 mo PFS in Refractory Low-Grade Serous OC (LGSOC)
In the first-in-human phase 1 FRAME trial (NCT03875820), 26 heavily pre-treated low-grade serous ovarian cancer patients received intermittent avutometinib 3.2 mg once daily (BIW, 3-weeks-on/1-off) plus continuous…
NCT03875820 - Trial result Spotlight
Melanoma
Pembrolizumab + ATRA (MDSC-Targeting) Posts 55% 5-Year OS in Metastatic Melanoma
All-trans retinoic acid (ATRA), a differentiating agent that depletes immunosuppressive myeloid-derived suppressor cells, was pulsed at 150 mg/m² orally on days −1/0/+1 of the first four pembrolizumab 200 mg Q3W…
NCT03200847 - Trial result
Kidney cancer
GAS6/AXL-Blocking Batiraxcept + Cabozantinib Yields 43% ORR in Heavily Pretreated ccRCC
Batiraxcept—a recombinant Fc fusion that soaks up GAS6 to shut down AXL signaling—was paired with cabozantinib in the phase 1b/2 NCT04300140 study. Among 51 previously treated clear-cell RCC patients given the…
NCT04300140 - Trial result Spotlight
Acute lymphoblastic leukemia
Fresh CD19 CAR T Achieves 100% MRD-Neg CR, 83% 3-yr OS in r/r Pediatric B-ALL
A point-of-care, second-generation 4-1BB CD19 CAR T product was manufactured fresh in 12 days and infused in the Phase I/II NCT04787263 trial (n = 19) enrolling children/young adults in very-high-risk first relapse…
NCT04787263 - Trial result
Acute lymphoblastic leukemia
Blinatumomab (CD19 BiTE) sees 28% attrition after toxic UK ALLR3 re‑induction in relapsed B‑ALL
Blinatumomab, a CD19‑directed bispecific T‑cell engager, was evaluated as post‑induction or salvage therapy in the Children’s Oncology Group Phase 3 AALL1331 trial (NCT02101853), which began with a UK ALLR3-inspired…
NCT02101853 - New trial Spotlight
Non-small cell lung cancer
Phase 2 study of Telisotuzumab Vedotin, c‑Met–targeted ADC with tubulin inhibitor, in NSCLC
AbbVie is testing telisotuzumab vedotin—a c‑Met–targeted antibody-drug conjugate with a tubulin inhibitor—in adults with previously treated, c-Met-overexpressing, EGFR-wild-type, advanced non-squamous NSCLC—a…
NCT06568939 Exploratory - New trial
Bladder and urothelial cancer
Phase 1 Trial of CA-4948 (IRAK4/FLT3 inhibitor) with Pembrolizumab
This Phase 1 study led by the National Cancer Institute assesses safety, tolerability, optimal dosing, and early efficacy of oral CA-4948 combined with intravenous pembrolizumab in patients with metastatic urothelial…
NCT06439836 Exploratory - New trial
Breast cancer
Phase IIIb Study: Ribociclib CDK4/CDK6 Inhibitor in HR+ HER2- Early Breast Cancer Adjuvant Setting
The trial evaluates safety and efficacy of ribociclib, a CDK4/CDK6 inhibitor, combined with standard adjuvant endocrine therapy in HR+ HER2- early-stage breast cancer patients, including a subgroup with Stage IIA…
NCT05827081 Registrational - New trial
Colorectal cancer
Phase 1 Abemaciclib (CDK4/CDK6 inhibitor) and 5-fluorouracil study in refractory colorectal cancer
This Phase 1 trial by the National Cancer Institute evaluates the safety, tolerability, and optimal dosing of abemaciclib combined with 5-fluorouracil in patients with metastatic, refractory colorectal cancer.…
NCT06654037 Exploratory - New trial
Lymphoma
Phase 1b trial: Tazemetostat EZH2 inhibitor with Zanubrutinib BTK inhibitor in indolent NHL.
This trial led by University of Utah evaluates the safety and preliminary efficacy of Tazemetostat (an EZH2 inhibitor) in combination with Zanubrutinib (a BTK inhibitor) and anti-CD20 monoclonal antibodies (rituximab…
NCT06824701 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1 trial of MGC028, an ADAM9-directed Topo I inhibitor ADC for advanced solid tumors.
This Phase 1 study led by MacroGenics evaluates safety, tolerability, and optimal dosing of MGC028 in adult patients with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors.…
NCT06723236 First-in-human - New trial Spotlight
Multiple solid tumors
Phase II ADC MATCH: sacituzumab govitecan (Trop‑2 ADC), enfortumab vedotin (nectin‑4 ADC), trastuzumab deruxtecan (HER2 ADC) trial
This Phase II study by the National Cancer Institute uses molecular screening with IHC assays to assign patients with advanced solid tumors lacking standard care options to one of three treatment cohorts. In each…
NCT06311214 Exploratory - New trial
Multiple solid tumors
Phase 1 SBO-154 trial of novel MUC1 ADC
This Phase 1 multicenter open-label study evaluates SBO-154, an investigational MUC1 antibody drug conjugate (ADC) for safety, tolerability, and preliminary efficacy in patients with advanced, relapsed, and…
NCT07042100 First-in-human - New trial
Other blood cancers and transplant
Phase 2 WU-CART-007: CD7-targeted CAR-T Cell Therapy for R/R T-ALL and T-LBL
This trial evaluates the efficacy of a single intravenous infusion of WU-CART-007—an anti-CD7 CAR-T cell therapy administered after lymphodepletion—in relapsed or refractory T-cell acute lymphoblastic leukemia and…
NCT06514794 Registrational - Trial result
Breast cancer
BRCA/PALB2 Mutations Cut Real-World PFS to 11 mo on First-Line CDK4/6i in HR+/HER2− mBC
Using France’s ESME registry, investigators retrospectively analyzed 4820 women with HR+/HER2− metastatic breast cancer who initiated first-line CDK4/6 inhibition plus endocrine therapy between 2013-2023 (palbociclib…
- Trial result
Breast cancer
Bria-IMT Vaccine + Pembrolizumab Shrinks Brain Mets in 5 of 6 Patients; Tumor-Agnostic Basket Trial Launches
Bria-IMT—an irradiated, GM-CSF–secreting allogeneic breast-cancer cell line (SV-BR-1-GM) that functions as an antigen-presenting vaccine—is moving into the single-site ASTRO-VAC CNS phase 1 basket (NCT06072612) after…
NCT06072612 - Trial result
Prostate cancer
6-mo Triple AR Blockade + Metastasis-Directed RT Yields 83% Deep PSA Response in Synchronous PSMA-PET Oligometastatic Prostate Cancer
In a pooled post-hoc look at the Phase 2 SOLAR (NCT03298087) and SATURN (NCT03902951) trials, 50 PSMA-PET-defined castrate-sensitive oligometastatic patients (≤5 lesions) received 6 months of leuprolide, abiraterone…
NCT03298087 - Trial result
Kidney cancer
VEGF-Blocker Bevacizumab + EGFR-TKI Erlotinib Delivers 72% ORR and 21-mo mPFS in Hereditary Papillary RCC
Bevacizumab (anti-VEGF antibody) plus erlotinib (EGFR tyrosine-kinase inhibitor) was tested in an open-label Phase 2 study (NCT01130519) enrolling 43 patients with fumarate-hydratase–mutated hereditary leiomyomatosis…
NCT01130519 - Trial result Spotlight
Acute lymphoblastic leukemia
Subcutaneous Blinatumomab Achieves 77% CR in Relapsed/Refractory B-ALL, Surpassing IV Benchmarks
Blinatumomab, a CD19×CD3 bispecific T-cell engager, was reformulated for subcutaneous (SC) delivery and evaluated in the phase 1/2 NCT04521231 study across 88 adults with relapsed/refractory B-cell ALL. Once-daily…
NCT04521231 - Trial result
Acute myeloid leukemia and MDS
Ven-CLAG-M Nabs 65% CR in Adverse-Risk or Relapsed AML
Venetoclax, a BCL-2 inhibitor, was layered onto the intensive CLAG-M backbone (cladribine 5 mg/m² ×5 days, cytarabine 1.5 g/m² ×5, mitoxantrone 16/18 mg/m² ×3, plus G-CSF priming) in a first-in-human Phase 1…
NCT04797767 - New trial Spotlight
Breast cancer
Phase 3 Inavolisib PI3K inhibitor trial in advanced breast cancer
This multicenter study by Hoffmann-La Roche compares inavolisib plus letrozole and a CDK4/6 inhibitor versus placebo with the same backbone in patients with PIK3CA-mutated, hormone receptor–positive, HER2–negative…
NCT06790693 Registrational - New trial
Breast cancer
Phase II Ivonescimab, a PD-1/VEGF bispecific antibody trial
This single arm study evaluates ivonescimab added to carboplatin and docetaxel administered every 3 weeks for 6 cycles as neoadjuvant therapy in early-stage triple negative breast cancer. Sponsored by Cedars-Sinai…
NCT07017673 Exploratory - New trial
Breast cancer
Phase 2 Mayo Ultrasound Marker: Enhancing lymph node imaging via twinkling artifact
This trial evaluates the safety and ultrasound performance of an optimized marker in women with biopsy-confirmed, node-positive breast cancer. Using ultrasound-guided placement followed by imaging and surgical…
NCT06999798 Exploratory - New trial
Breast cancer
Phase I/II Trial: Naxitamab (GD2 mAb) + Sacituzumab Govitecan (TROP2-directed ADC)
This study evaluates safety, dosing, and efficacy of the combination in metastatic triple-negative breast cancer patients eligible for second-line or later treatment. Conducted by MD Anderson in Houston, the trial…
NCT07011654 Exploratory - New trial
Breast cancer
Phase II trial of darolutamide, an androgen receptor inhibitor, in early-stage AR+ TNBC
This study compares neoadjuvant standard chemotherapy plus immunotherapy with versus without darolutamide in stage II-IIIA AR+ triple-negative breast cancer at Nashville, sponsored by Vandana Abramson. It evaluates…
NCT07016399 Exploratory - New trial
Breast cancer
Phase 2/3 trial of Izalontamab Brengitecan, EGFR/HER3 bispecific ADC with topoisomerase inhibition
This randomized, open-label study compares iza-bren monotherapy versus physician’s choice in first-line metastatic triple-negative or ER-low, HER2-negative breast cancer patients ineligible for anti-PD(L)1 or…
NCT06926868 Registrational - New trial
Non-small cell lung cancer
Phase II GT103 mAb targeting complement factor H with pembrolizumab for STK11 NSCLC
This study tests GT103 with pembrolizumab as a combination immunotherapy for advanced STK11 mutant non‐small cell lung cancer. Sponsored by Roswell Park Cancer Institute, the trial evaluates GT103’s novel complement…
NCT07017829 Exploratory - New trial
Small cell lung cancer
Phase 2 trial of BMS-986489, atigotatug (anti-fucosyl-GM1 monoclonal antibody) plus PD-1 inhibitor, in SCLC consolidation
An open-label randomized study compares the fixed-dose combination of atigotatug and nivolumab (BMS-986489) with standard durvalumab consolidation following chemoradiotherapy in limited-stage small-cell lung cancer.…
NCT06773910 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.